Recent findings in breast cancer, in which the mTOR/Akt/PI3K axis is the most frequently enhanced oncogenic pathway, have suggested a possible synergy for ovarian cancer patients between PI3K inhibitors and poly-adenylate ribose polymerase (PARP) inhibitors. This evidence concerns the gene PIK3CA and ovarian carcinoma.